Azenta, Inc. (AZTA)
NASDAQ:AZTA
Want to see AZTA full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
0.13Last Year’s EPS
0.19Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call was mixed. Positive operational and recurring-revenue trends (strong biorepository growth, improved on-time delivery, faster RNA-Seq turnaround, solid cash position, and targeted cost savings) coexist with significant near-term challenges: organic revenue decline, notable margin compression, large goodwill impairments (~$149M), automated storage quality remediation and delayed large-capex orders, and a guidance reset lowering FY26 growth and profitability expectations. Management reiterated long-term conviction in strategic priorities and outlined actions (leadership changes, ABS deployment, cost reductions, M&A integration) to address execution gaps, but near-term results and uncertainty weighed on the quarter.Company Guidance
Recurring Revenue Strength — Biorepositories and Services
Sample repository/biorepository solutions (≈40% of SMS) delivered high single-digit growth and supported steady growth in product services, consumables and instruments, reinforcing a durable recurring revenue base that helped partially offset capital equipment softness.
Operational Execution Improvements
Notable operational gains from the Azenta Business System: on-time delivery in consumables & instruments improved from ~15% to ~70%, and Lightning RNA-Seq turnaround time was reduced from ~20 days to 5 days (launched) — a market differentiator.
Strong Balance Sheet and Positive Cash Flow
Quarter-end cash, cash equivalents and marketable securities of $565 million, no debt outstanding, free cash flow of $5 million in Q2, and modest capex of ~$7 million, providing financial flexibility to invest and pursue M&A.
Strategic M&A Execution — UK Biocentre
Acquired UK Biocentre (UKBC) in March; integration progressing as planned, contributing ~$1 million to revenue in the quarter and expanding European biorepository footprint and operational hub capabilities.
Cost Actions and Organizational Changes
Partial restructuring implemented yielding ~$7 million of annualized savings (≈$3 million realized in-year), engineering reorganized into three teams (new product, current projects, sustaining), and hiring of Trey Martin to lead Multiomics transformation to improve commercial discipline and execution.
Guidance and Expected Sequential Improvement
Updated FY26 guidance provides clarity (reported revenue $603M–$621M; organic revenue down ~2% to up 1%). Management expects sequential margin recovery in H2 with adjusted EBITDA margins moving into low double-digit range in Q3 and further improvement in Q4.
AZTA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AZTA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $24.61 | $18.38 | -25.31% |
Feb 04, 2026 | $36.91 | $28.49 | -22.81% |
Nov 21, 2025 | $30.00 | $34.89 | +16.30% |
Aug 05, 2025 | $32.41 | $26.90 | -17.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Azenta, Inc. (AZTA) report earnings?
Azenta, Inc. (AZTA) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Azenta, Inc. (AZTA) earnings time?
Azenta, Inc. (AZTA) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AZTA EPS forecast?
AZTA EPS forecast for the fiscal quarter 2026 (Q3) is 0.13.
